pPACK-SPIKE™ Beta (B.1.351) Variant Lentivector Packaging Mix

Overview

Safely study the spike protein from emerging SARS-CoV-2 variants 

Classified as a variant of concern by the Centers for Disease Control (CDC) in the United States, the SARS-CoV-2 Beta Variant, originally referred to as variant B.1.351, was initially observed in South Africa and has since spread globally. With the pPACK-SPIKE™ Beta (B.1.351) Variant Spike Protein Lentivector Packaging Mix, you can safely characterize the SARS-CoV-2 S1 spike protein from lineage Beta (B.1.351), which contains the following mutations:

• L18F
• D80A
• D215G
• Δ242-244
• R246I
• K417N
• E484K
• N501Y
• D614G
• A701V

Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE Beta (B.1.351) Variant Spike Protein Lentivector Packaging Mix speeds and simplifies preparation of lentiviral particles pseudotyped with the SARS-CoV-2 L18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y, D614G, A701V spike glycoprotein, making it an ideal reagent for vaccine and antiviral drug discovery projects.

Based on SBI’s highly cited pPACKH1 packaging system but with a truncated L18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y, D614G, A701V Spike protein [1] replacing the standard VSV-G envelope protein, the pPACK-SPIKE Beta (B.1.351) Variant Spike Protein Packaging Mix consists of three plasmids that produce all of the structural and replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, L18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y, D614G, A701V “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics.

For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for any pPACK-SPIKE study, or for creating lentivirus particles pseudotyped with the envelope protein of your choice.

• Based on SBI’s popular and highly cited pPACKH1 Packaging System
• Uses codon-optimized SARS-CoV-2 “S” protein from variant Beta (B.1.351, originally found in South Africa) in place of VSV-G envelope protein
• Spike protein mutations are L18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y, D614G, A701V
• Ideal for vaccine and antiviral efficacy studies under BSL2 conditions
• Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
• Compare with our full range of pPACK-SPIKE S protein pseudotyped lentiviruses to better understand emerging variants
• Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control

pPACK-SPIKE Beta (B.1.351) Variant Spike Protein Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as in a convenient kit format that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution.

See all of the available pPACK-SPIKE S protein variants:

1. Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9. PMCID: PMC7100515.